Difference between revisions of "Lapuleucel-T (DN24-02)"
Warner-admin (talk | contribs) |
m |
||
| Line 18: | Line 18: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Bladder cancer medications]] | + | [[Category:Bladder cancer medications (investigational)]] |
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 21:26, 25 April 2022
General information
Class/mechanism: Autologous cellular immunotherapy, designed to stimulate a response against HER2/Neu receptor. Autologous peripheral blood mononuclear cells, which include antigen presenting cells (APCs), are obtained via leukapheresis. They are then activated ex vivo with a recombinant fusion protein.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
Also known as
- Code name: DN24-02